After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...
Physicians recommend that patients with chronic obstructive pulmonary disease (COPD) quit smoking and use steroids, ...
Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.
Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...
The growing prevalence of COPD among women can be attributed to a combination of biological, environmental, and societal ...
Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...
UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...
Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...